FemHealth Ventures

Cercle advances women's healthcare by unlocking access to insights. Cercle’s platform, the Cercle Biomedical Graph™, transforms healthcare data at scale into real-time, high-quality insights that women's healthcare providers use to run more efficient businesses and provide personalized care.

Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company’s primary focus is on its lead asset, RE104, a proprietary serotonergic psychedelic compound designed as a fast-acting and durable antidepressant for patients experiencing postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which comprises compounds aimed at achieving more selective serotonin receptor activity with reduced psychoactivity, thereby broadening the potential applications for chronic treatment scenarios. The company seeks to address significant gaps in mental health care through innovative pharmacological approaches.

AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that will improve clinical practice and help reduce patient mortality.

Rejoni, Inc. is a medical device company based in Bedford, Massachusetts, founded in 2020. It specializes in developing and commercializing innovative solutions aimed at enhancing the outcomes of gynecological surgical procedures. The company focuses on preventing scar formation after intrauterine interventions, addressing both acute and chronic risks associated with such procedures. By utilizing biomaterials, Rejoni creates gynecological products that prioritize women's health, enabling patients to achieve their desired quality of life both now and in the future.

The mission of the Fogarty Institute for Innovation is to promote medical innovation by providing support to promising innovators and researchers as they transform their creative ideas into practical solutions to improve patient care. They offer mentorship and education at every step of the process, coordinating access to intellectual, physical, and financial resources to propel medical concepts from initiation to application.

Raydiant Oximetry, Inc. is a medical device company established in 2015 and headquartered in Mountain View, California. The company specializes in the development of a low-cost, non-invasive device that monitors fetal oxygen levels during labor, with the aim of improving health outcomes for mothers and their babies. By providing real-time data on fetal oxygenation, Raydiant Oximetry's technology seeks to enhance patient care, reduce the occurrence of unnecessary cesarean sections, and lower healthcare costs associated with childbirth. The company's innovations are designed to address potential birth injuries and minimize over-intervention in the delivery process, ultimately striving to improve the overall experience and safety of childbirth.

Nymbl Science provides training that helps maintain and improve balance for a better quality of life, at every age. The company's mission is to use medical science and mobile technology to improve balance and prevent falls. Nymbl is a scientifically validated digital balance training program that will prevent 1 million falls. It’s an effective and engaging way to train the brain and body to work together, using just a smartphone and in only 10 minutes a day, allowing older adults to preserve and enhance their freedom and enjoyment of life.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.